Metsera is a clinical-stage biopharmaceutical company developing next-generation peptide medicines for obesity and metabolic diseases, built on its HALO™ lipidation and MOMENTUM™ oral delivery platforms. The company has three medicines in the clinic, including MET-097i, MET-233i and MET-002, and is advancing additional NuSH analog peptides and unimolecular combinations. MET-097i, a fully-biased, ultra-long acting injectable GLP-1 RA, showed 7.5% body-weight reduction at day 36 and a 380-hour half-life in Phase 1/2 testing and is now in a randomized 16-week Phase 2 trial. MET-233i (an ultra-long acting amylin analog) and MET-002 (an oral GLP-1 RA peptide) have initiated clinical studies. Metsera says its HALO™ platform enables near-albumin half-lives and monthly, titration-free dosing, while MOMENTUM™ aims to deliver injectable-like oral peptide efficacy at lower doses. The company has built a large proprietary peptide library and is pursuing combinations, co-formulations, and scaled manufacturing to support late-stage development. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies designed to address obesity and metabolic diseases. Its pipeline is sourced from a proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. Development programs include a Phase 1 fully-biased GLP-1 receptor agonist, a dual amylin/calcitonin receptor agonist (DACRA) combined with the GLP-1 agonist, a unimolecular GGG (GLP-1, GIP, Glucagon), and an oral peptide delivery platform with two IND-ready candidates. The company says its portfolio is engineered for class-leading duration of effect and aims to address future needs such as weight maintenance, muscle preservation, less-frequent dosing, improved efficacy and tolerability, and better patient access. Founded in 2022 by Population Health Partners and ARCH Venture Partners and led by CEO Clive Meanwell, Metsera is positioning to rapidly advance its clinical-stage pipeline. Metsera has raised $290 million in financing to support development from its New York City base.

Total raised

$505M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2024